Arizón J M, Anguita M, Vallés F, Montero A, Sancho M, López-Rubio F, Latre J M, Calleja F, Casares J, Román M
Heart Transplantation Unit, Hospital Reina Sofía, University of Córdoba, Spain.
J Heart Lung Transplant. 1993 May-Jun;12(3):445-8; discussion 448-9.
Prednisone is widely used by most heart transplant units, despite its frequent side effects. Deflazacort, a new oral synthetic steroid with fewer side effects, has not been studied in heart transplant patients. Our initial experience with 26 heart transplant patients in whom prednisone was replaced by deflazacort at 11 +/- 11 months after transplantation is reported. After the switch to deflazacort, a significant decreased was noted in glycemia, total cholesterol, and LDL-cholesterol (p < 0.001). No difference was noted in severity or frequency of rejection and infection between patients being treated with deflazacort and another 26 patients who continued to be treated with prednisone over a comparable period of time after transplantation.
尽管泼尼松有诸多常见副作用，但大多数心脏移植单位仍广泛使用。去氟可特是一种新型口服合成类固醇，副作用较少，尚未在心脏移植患者中进行研究。本文报告了我们对26例心脏移植患者的初步经验，这些患者在移植后11±11个月用去氟可特替代了泼尼松。改用去氟可特后，血糖、总胆固醇和低密度脂蛋白胆固醇显著降低（p<0.001）。在移植后的相当一段时间内，接受去氟可特治疗的患者与另外26例继续接受泼尼松治疗的患者在排斥反应和感染的严重程度或频率方面没有差异。
